Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 3/20 | 0.65 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 6/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.55 |
| ▸ | USP2 | O75604 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5075295 | 0.90 | DPP4 (0.71) | DPP4POLBSIRT5MEN1KMT2A | |
| SCHEMBL5075051 | 0.82 | DPP4 (0.70) | DPP4POLBSIRT5MEN1KMT2A | |
| SCHEMBL555020 | 0.82 | DPP4 (1.00) | DPP4POLBSIRT5MEN1KMT2A | |
| SCHEMBL5073403 | 0.82 | DPP4 (0.79) | DPP4POLBSIRT5MEN1KMT2A | |
| SCHEMBL5075053 | 0.80 | MEN1 (0.75) | DPP4POLBSIRT5MEN1KMT2A | |
| SCHEMBL7562242 | 0.80 | DPP4 (0.84) | DPP4POLBSIRT5MEN1KMT2A | |
| SCHEMBL5075030 | 0.79 | MEN1 (0.81) | DPP4POLBSIRT5MEN1KMT2A | |
| SCHEMBL5075029 | 0.79 | POLB (0.84) | DPP4POLBSIRT5MEN1KMT2A | |
| SCHEMBL5639735 | 0.78 | DPP4 (0.74) | DPP4POLBSIRT5MEN1KMT2A | |
| SCHEMBL22800900 | 0.78 | DPP4 (0.74) | DPP4POLBSIRT5MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020161001-A1 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2002-10-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161001-A1 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP3 | DPP4 1/4885POLB 3194/4885SIRT5 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.